全球罕见肾臟疾病治疗市场研究报告——2023-2030 年行业分析、规模、份额、增长、趋势和预测

全球对罕见肾脏病治疗市场的需求将从 2022 年的 70.4 亿美元增加到 2030 年的近 151.3 亿美元，复合年增长率为 10.04% 在 2023-2030 年的研究期间预计将达到

罕见的肾臟疾病是一组影响肾臟并可能导致肾衰竭的疾病。 它因基因突变、感染性疾病、自身免疫性疾病等多种因素而发展，可出现肾功能衰竭、蛋白尿、高血压等多种症状。 罕见的肾臟疾病通常采用药物治疗、生活方式改变、透析和移植相结合的方法进行治疗。 由于流行率低和知识匮乏，这些疾病往往很困难。

市场动态：

对更有效的罕见肾臟疾病治疗和治愈方法的需求不断增长，推动了该行业的兴起。 此外，人们对这些疾病的认识和了解的提高有望推动罕见肾病治疗市场的扩大。 此外，关于罕见肾臟疾病的研究和知识的增加也促进了市场的增长。 此外，对更有效的治疗和治疗罕见肾臟疾病的需求不断增加，也促进了市场的增长。 然而，高昂的处理成本可能会阻碍市场增长。

这份研究报告解释了波特的五力模型、市场吸引力分析和价值链分析。 这些工具可帮助您清楚地了解您的行业结构并评估您在全球范围内的竞争吸引力。 此外，这些工具还对全球罕见肾病治疗市场的每个细分市场进行了全面评估。 罕见肾臟疾病治疗行业的发展和趋势为这项研究提供了一种整体方法。

市场细分：

本部分按国家/地区提供详细的细分数据，以帮助您确定每种产品/服务的目标受众和未来商机。

按药物类别

• □替代疗法
• 单克隆抗体
• 其他

按展示

• 法布里病
• 非典型溶血性尿毒症综合征
• 狼疮性肾炎
• 肾病性胱氨酸增多症
• 其他

按分销渠道

• 医院药房
• 零售药房
• 在线销售

按地区分析：

本节涵盖区域展望，重点介绍北美、欧洲、亚太地区、拉丁美洲、中东和非洲对罕见肾臟疾病治疗市场当前和未来的需求。 此外，我们还关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的综合概况和全球竞争格局的详细视图。 罕见肾病治疗市场的主要参与者是 Calliditas Therapeutics AB、GSK plc、Aurinia Pharmaceuticals Inc.、Amicus Therapeutics Inc.、Shire（武田製药）、赛诺菲、Advicenne、Alexion Pharmaceuticals Inc、Horizo□□n Therapeutics plc、Otsuka Pharmaceutical Co. Ltd ., Reata Pharmaceuticals Inc. 本节概述了竞争格局，包括各种战略发展，如主要併购、未来能力、合作伙伴关係、财务概览、联合研究、新产品开发和新产品发布。

内容

第一章前言

• 报告内容
  • 目的
  • 目标受众
  • USP（独特的销售建议）及其提供的内容
• 调查范围
• 调查方法
  • 市场调研流程
  • 市场研究方法

第 2 章执行摘要

• 市场亮点
• 全球市场概况

第 3 章罕见肾脏病治疗 - 行业分析

• 简介 - 市场动态
• 市场驱动力
• 市场製约因素
• 机会
• 行业趋势
• 波特的五力分析
• 市场吸引力分析
  • 按药物类别进行的市场吸引力分析
  • 按适应症分类的市场吸引力分析
  • 按分销渠道进行的市场吸引力分析
  • 市场吸引力分析：按地区

第四章价值链分析

• 价值链分析
• 原材料分析
  • 原材料清单
  • 原材料製造商名单
  • 主要原材料价格走势
• 潜在买家名单
• 营销渠道
  • 直接营销
  • 间接营销
  • 市场发展趋势

第 5 章 COVID-19 爆发的影响分析

第 6 章罕见肾脏病治疗的全球市场分析：按药物分类

• 按药物类别汇总
• 过去和未来的数据
• 按药物类别分析
• □替代疗法
• 单克隆抗体
• 其他

第 7 章罕见肾脏病疗法的全球市场分析：按适应症分类

• 功效概述
• 过去和未来的数据
• 适应症分析
• 法布里病
• 非典型溶血性尿毒症综合征
• 狼疮性肾炎
• 肾病性胱氨酸增多症
• 其他

第 8 章稀有肾臟药物的全球市场销售分析：按分销渠道

• 按分销渠道概述
• 过去和未来的数据
• 按分销渠道分析
• 医院药房
• 零售药房
• 在线销售

第 9 章罕见肾脏病疗法的全球市场销售分析：按地区

• 按地区进行的销售前景分析
• 介绍销售分析
• 北美销售分析
  • 概览、历史和预测销售分析
  • 北美各部门的销售分析
  • 北美销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史和预测销售分析
  • 按细分市场进行的欧洲销售分析
  • 按国家/地区划分的欧洲销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 意大利销售分析
  • 俄罗斯销售分析
  • 其他欧洲销售分析
• 亚太地区销售分析
  • 概览、历史和预测销售分析
  • 亚太地区各部门的销售分析
  • 亚太国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本的销售分析
  • 韩国销售分析
  • 澳大利亚销售分析
  • 其他亚太地区销售分析
• 拉丁美洲销售分析
  • 概览、历史和预测销售分析
  • 拉丁美洲各部门的销售分析
  • 拉丁美洲国家/地区的销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利的销售分析
  • 其他拉丁美洲销售分析
• 中东和非洲销售分析
  • 概览、历史和预测销售分析
  • 中东和非洲各细分市场的销售额分析
  • 中东和非洲国家/地区的销售分析
  • 沙特阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 其他中东和非洲销售分析

第 10 章：罕见肾病治疗公司的竞争状况

• 稀有肾臟治疗市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他扩展

第11章公司简介

• 前 10 名公司的市场份额分析
• 市场集中度
• Calliditas Therapeutics AB
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 葛兰素史克公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• Aurinia 製药公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• Amicus Therapeutics Inc.
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• Shire（武田製药有限公司）
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 赛诺菲
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 建议
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• Alexion 製药公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• Horizo□□n Therapeutics plc
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• 大冢製药有限公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势
• Reata 製药公司
  • 公司简介
  • 企业收入
  • 产品介绍
  • 近期趋势

注意：在公司简介、财务细节、近期发展等方面，基于可用信息，私人控股公司可能不包括在内。

The global demand for Rare Kidney Diseases Treatment Market is presumed to reach the market size of nearly USD 15.13 BN by 2030 from USD 7.04 BN in 2022 with a CAGR of 10.04% under the study period 2023 - 2030.

Rare kidney diseases are a group of conditions that affect the kidneys and can lead to kidney failure. They can be caused by various factors, including genetic mutations, infections, and autoimmune disorders, and may have a wide range of symptoms, including kidney damage, proteinuria, and high blood pressure. Rare kidney disease treatment often involves a combination of medications, lifestyle modifications, and dialysis or transplantation. It is often challenging due to the low prevalence and lack of knowledge about these conditions.

Market Dynamics:

The increasing demand for more effective treatments and therapies for rare kidney diseases has contributed to the rise of this field. Moreover, the growing awareness and understanding of these conditions may drive the rare kidney disease treatment market to increase. Furthermore, increased research and knowledge about rare kidney diseases have led to market growth. In addition, the increasing demand for more effective treatments and therapies for rare kidney diseases has contributed to the market's rise. However, the high cost of treatment may hamper the market growth.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of rare kidney diseases treatment. The growth and trends of rare kidney diseases treatment industry provide a holistic approach to this study.

Market Segmentation:

This section of the rare kidney diseases treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Enzyme Replacement Therapy
• Monoclonal Antibodies
• Others

By Indication

• Fabry Disease
• Atypical Hemolytic Uremic Syndrome
• Lupus Nephritis
• Nephropathic Cystinosis
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Sales

Regional Analysis:

This section covers the regional outlook, which accentuates current and future demand for the Rare Kidney Diseases Treatment market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the rare kidney diseases treatment market include Calliditas Therapeutics AB, GSK plc, Aurinia Pharmaceuticals Inc., Amicus Therapeutics Inc., Shire (Takeda Pharmaceutical Company Limited), Sanofi, Advicenne, Alexion Pharmaceuticals Inc., Horizon Therapeutics plc, Otsuka Pharmaceutical Co. Ltd., Reata Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . RARE KIDNEY DISEASES TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Indication
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1 Overview by Drug Class
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Drug Class
• 6.4 Enzyme Replacement Therapy Historic and Forecast Sales by Regions
• 6.5 Monoclonal Antibodies Historic and Forecast Sales by Regions
• 6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET ANALYSIS BY INDICATION

• 7.1 Overview by Indication
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Indication
• 7.4 Fabry Disease Historic and Forecast Sales by Regions
• 7.5 Atypical Hemolytic Uremic Syndrome Historic and Forecast Sales by Regions
• 7.6 Lupus Nephritis Historic and Forecast Sales by Regions
• 7.7 Nephropathic Cystinosis Historic and Forecast Sales by Regions
• 7.8 Others Historic and Forecast Sales by Regions

8 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET SALES ANALYSIS BY DISTRIBUTION CHANNEL

• 8.1 Overview by Distribution Channel
• 8.2 Historical and Forecast Data
• 8.3 Analysis by Distribution Channel
• 8.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 8.5 Retail Pharmacies Historic and Forecast Sales by Regions
• 8.6 Online Sales Historic and Forecast Sales by Regions

9 . GLOBAL RARE KIDNEY DISEASES TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

• 9.1. Regional Outlook Sales Analysis
• 9.2. Introduction Sales Analysis
• 9.3. North America Sales Analysis
  • 9.3.1. Overview, Historic and Forecast Sales Analysis
  • 9.3.2. North America By Segment Sales Analysis
  • 9.3.3. North America By Country Sales Analysis
  • 9.3.4. United State Sales Analysis
  • 9.3.5. Canada Sales Analysis
  • 9.3.6. Mexico Sales Analysis
• 9.4. Europe Sales Analysis
  • 9.4.1. Overview, Historic and Forecast Sales Analysis
  • 9.4.2. Europe by Segment Sales Analysis
  • 9.4.3. Europe by Country Sales Analysis
  • 9.4.4. United Kingdom Sales Analysis
  • 9.4.5. France Sales Analysis
  • 9.4.6. Germany Sales Analysis
  • 9.4.7. Italy Sales Analysis
  • 9.4.8. Russia Sales Analysis
  • 9.4.9. Rest Of Europe Sales Analysis
• 9.5. Asia Pacific Sales Analysis
  • 9.5.1. Overview, Historic and Forecast Sales Analysis
  • 9.5.2. Asia Pacific by Segment Sales Analysis
  • 9.5.3. Asia Pacific by Country Sales Analysis
  • 9.5.4. China Sales Analysis
  • 9.5.5. India Sales Analysis
  • 9.5.6. Japan Sales Analysis
  • 9.5.7. South Korea Sales Analysis
  • 9.5.8. Australia Sales Analysis
  • 9.5.9. Rest Of Asia Pacific Sales Analysis
• 9.6. Latin America Sales Analysis
  • 9.6.1. Overview, Historic and Forecast Sales Analysis
  • 9.6.2. Latin America by Segment Sales Analysis
  • 9.6.3. Latin America by Country Sales Analysis
  • 9.6.4. Brazil Sales Analysis
  • 9.6.5. Argentina Sales Analysis
  • 9.6.6. Peru Sales Analysis
  • 9.6.7. Chile Sales Analysis
  • 9.6.8. Rest of Latin America Sales Analysis
• 9.7. Middle East & Africa Sales Analysis
  • 9.7.1. Overview, Historic and Forecast Sales Analysis
  • 9.7.2. Middle East & Africa by Segment Sales Analysis
  • 9.7.3. Middle East & Africa by Country Sales Analysis
  • 9.7.4. Saudi Arabia Sales Analysis
  • 9.7.5. UAE Sales Analysis
  • 9.7.6. Israel Sales Analysis
  • 9.7.7. South Africa Sales Analysis
  • 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE RARE KIDNEY DISEASES TREATMENT COMPANIES

• 10.1. Rare Kidney Diseases Treatment Market Competition
• 10.2. Partnership/Collaboration/Agreement
• 10.3. Merger And Acquisitions
• 10.4. New Product Launch
• 10.5. Other Developments

11 . COMPANY PROFILES OF RARE KIDNEY DISEASES TREATMENT INDUSTRY

• 11.1. Top 10 Company Share Analysis
• 11.2. Market Concentration Rate
• 11.3. Calliditas Therapeutics AB
  • 11.3.1. Company Overview
  • 11.3.2. Company Revenue
  • 11.3.3. Products
  • 11.3.4. Recent Developments
• 11.4. GSK plc
  • 11.4.1. Company Overview
  • 11.4.2. Company Revenue
  • 11.4.3. Products
  • 11.4.4. Recent Developments
• 11.5. Aurinia Pharmaceuticals Inc.
  • 11.5.1. Company Overview
  • 11.5.2. Company Revenue
  • 11.5.3. Products
  • 11.5.4. Recent Developments
• 11.6. Amicus Therapeutics Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Company Revenue
  • 11.6.3. Products
  • 11.6.4. Recent Developments
• 11.7. Shire (Takeda Pharmaceutical Company Limited)
  • 11.7.1. Company Overview
  • 11.7.2. Company Revenue
  • 11.7.3. Products
  • 11.7.4. Recent Developments
• 11.8. Sanofi
  • 11.8.1. Company Overview
  • 11.8.2. Company Revenue
  • 11.8.3. Products
  • 11.8.4. Recent Developments
• 11.9. Advicenne
  • 11.9.1. Company Overview
  • 11.9.2. Company Revenue
  • 11.9.3. Products
  • 11.9.4. Recent Developments
• 11.10. Alexion Pharmaceuticals Inc.
  • 11.10.1. Company Overview
  • 11.10.2. Company Revenue
  • 11.10.3. Products
  • 11.10.4. Recent Developments
• 11.11. Horizon Therapeutics plc
  • 11.11.1. Company Overview
  • 11.11.2. Company Revenue
  • 11.11.3. Products
  • 11.11.4. Recent Developments
• 11.12. Otsuka Pharmaceutical Co. Ltd.
  • 11.12.1. Company Overview
  • 11.12.2. Company Revenue
  • 11.12.3. Products
  • 11.12.4. Recent Developments
• 11.13. Reata Pharmaceuticals Inc.
  • 11.13.1. Company Overview
  • 11.13.2. Company Revenue
  • 11.13.3. Products
  • 11.13.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• Enzyme Replacement Therapy Market Sales by Geography (USD MN)
• Monoclonal Antibodies Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Indication (USD MN)
• Fabry Disease Market Sales by Geography (USD MN)
• Atypical Hemolytic Uremic Syndrome Market Sales by Geography (USD MN)
• Lupus Nephritis Market Sales by Geography (USD MN)
• Nephropathic Cystinosis Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Sales Market Sales by Geography (USD MN)
• Global Rare Kidney Diseases Treatment Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Rare Kidney Diseases Treatment Report
• Market Research Process
• Market Research Methodology
• Global Rare Kidney Diseases Treatment Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Indication
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Enzyme Replacement Therapy Market Sales by Geography (USD MN)
• Monoclonal Antibodies Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Indication (USD MN)
• Fabry Disease Market Sales by Geography (USD MN)
• Atypical Hemolytic Uremic Syndrome Market Sales by Geography (USD MN)
• Lupus Nephritis Market Sales by Geography (USD MN)
• Nephropathic Cystinosis Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Pharmacies Market Sales by Geography (USD MN)
• Online Sales Market Sales by Geography (USD MN)
• Global Market by Revenue
• North America Market by Revenue
• Europe Market by Revenue
• Asia Pacific Market by Revenue
• Latin America Market by Revenue
• Middle East & Africa Market by Revenue
• Recent Development in Industry
• Top Company Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.